New daily weight loss pill approved in UK
The UK has approved a new daily weight loss pill, making it the first such approval in Europe.
The Full Story
A plain summary built from the channels that reported this story.
The UK has approved a new daily weight loss pill, the first such approval in Europe. The drug, called Fandao, is made by the company behind Mounjaro. It works in a similar way to existing GLP-1 medications, suppressing appetite and making people feel less hungry. But unlike some other pills, it does not need to be taken on an empty stomach and has fewer restrictions around when it is taken.
Speaking on 5 News, Dr Samir Aziz explained that Fandao is a non-peptide, a smaller chemical compared with other weight loss drugs. He said it is very similar to Weygevy, another GLP-1 pill, but with a simpler dosing routine. The pill is designed for daily use and has been described by manufacturers as a "pill for life". Dr Aziz stressed that it should not be given to everyone. He said obesity is a huge problem globally and the medication needs to be used appropriately, adding that one size does not fit all.
Eligibility currently includes people with a body mass index of 30, or 27 with a comorbidity such as diabetes. The pill appears to be less potent than injectable versions. Dr Aziz noted that over 22 weeks, patients taking Fandao can expect an average weight loss of 11%. That compares with 13 to 16% for the Weygevy pill and greater losses for injectables, which go straight into the bloodstream.
Side effects are broadly the same across these drugs. Dr Aziz warned that people with a history of pancreatitis or thyroid issues should be cautious. He said the drugs are positive for many health benefits and he could not see a negative. But he also acknowledged that long-term effects are unknown, saying "we don't know what the long-term effects will be in 20, 30 years time."
The approval marks another step in the growing market for weight loss treatments. While the new pill offers convenience, experts caution that it is not a magic solution and must be used for the right patients. As Dr Aziz put it, "we can't be giving it out to everybody."
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | Channel 5 |
|---|---|
| A new weight-loss pill called Fandao was made by the company that produces Mounjaro. | |
| The pill is available to people with a BMI of 30, or 27 with a comorbidity such as diabetes. | |
| The pill leads to an average weight loss of 11% over 22 weeks. |
Channel Perspectives
What each channel focused on, with key quotes.
The coverage focused on the practical differences between the new daily pill and existing weight loss medications, including effectiveness, restrictions, and eligibility. The tone was balanced, with a medical expert explaining both benefits and uncertainties. The segment also briefly touched on unrelated good news about hepatitis, but the main story remained the pill.
- “So, the fact is that this one is what we describe as a non-peptide. It's a smaller chemical. It's very similar to the Weygevy, in that it's a GLP-1 medication.”
- “We can't be giving it out to everybody. Obesity, we know, is a huge problem globally. We need to use the medication appropriately.”
- “But I think looking overall it's really we don't know what the long-term effects will be in 20, 30 years time.”
Broadcast Timeline
News broadcasts tracked for this story, in time order.